Understanding the Risk of Secondary Cancers for Chronic Lymphocytic Leukemia Patients
Join HealthTree for this webinar discussing the risk of developing secondary cancers for CLL patients. Dr. Brian Hill from the Cleveland Clinic will be joining us for a presentation and Q&A.
Dalton introduces the agenda of the event and featured speaker Brian Hill MD, PhD
Dr. Hill talks about the risk of secondary cancers
Type your questions in the chat, we will answer them!
Dalton Bean
Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Brian Hill MD, PhD
Dr. Hill is the Director of the Lymphoid Malignancies Program and a Staff Physician in the Cleveland Clinic Taussig Cancer Institute. His clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma. He is the principal investigator of multiple on-going clinical trials of new cancer treatments including novel cellular therapies and has published extensive research articles pertaining to these topics. He serves as the Chairman of the Pharmacy & Therapeutics (P&T) Committee within the Department of Hematology and Medical Oncology, the Cleveland Clinic Board of Governors Professional Advancement Council and on the editorial board of several peer reviewed journals. He is an Associate Professor of Medicine of the Cleveland Clinic Lerner College of Medicine is an active member of the Case Comprehensive Cancer Center, American Society of Hematology (ASH), and the Center for International Blood and Marrow Transplant Research (CIBMTR) and committee member of the National Comprehensive Cancer Network (NCCN).